Coronary Stent Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Coronary stents are small, expandable mesh tubes implanted in narrowed or blocked coronary arteries to restore blood flow, most commonly during percutaneous coronary intervention (PCI) procedures. The global market was valued at about $13.24 billion in 2025 and is projected to grow at roughly 4.8% annually through the early 2030s. Demand is anchored in the high and rising prevalence of coronary artery disease, which remains a leading cause of mortality worldwide.

• •Market size in 2025: approximately $13.24 billion globally.
• •Forecast CAGR: about 4.8% per year through the early 2030s.
• •Drug-eluting stents account for the majority share of product revenue.

The principal driver is the increasing global incidence of coronary artery disease, linked to aging populations, diabetes, obesity, and sedentary lifestyles. Expanded access to catheterization laboratories and PCI in developing markets is broadening the patient pool eligible for stenting. Continued innovation in stent technology, including improved biocompatible polymers and bioabsorbable scaffolds, is also supporting procedure volumes and premium pricing.

• •Rising prevalence of cardiovascular disease and aging demographics in both developed and emerging economies.
• •Greater adoption of minimally invasive PCI procedures over open surgical interventions.
• •Technology improvements in drug coatings, thinner struts, and bioresorbable materials.

By product type, the market is dominated by drug-eluting stents (DES), followed by bare-metal stents (BMS) and the smaller but evolving segment of bioresorbable vascular scaffolds (BVS). North America holds the largest regional share, supported by high procedure volumes, established reimbursement, and early adoption of advanced devices. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure, rising disposable income, and large untreated patient populations in countries such as China and India.

• •Product segmentation: drug-eluting, bare-metal, and bioabsorbable stents, with DES leading.
• •North America: largest revenue share, driven by procedure volume and reimbursement coverage.
• •Asia-Pacific: fastest-growing region due to healthcare expansion and rising CAD prevalence.

What are the recent trends and outlook?

The market is shifting toward next-generation drug-eluting stents with thinner struts, biocompatible or polymer-free coatings, and improved deliverability in complex lesions. Bioabsorbable scaffolds, though still a smaller segment, continue to attract R&D investment aimed at overcoming earlier clinical setbacks. Over the forecast period, the market is expected to maintain mid-single-digit growth, supported by demographic trends, broader access to PCI in emerging markets, and gradual replacement of older stent platforms with newer-generation devices.

• •Move toward thinner-strut DES and polymer-free or biodegradable coatings for improved vessel healing.
• •Ongoing R&D in bioresorbable vascular scaffolds despite earlier commercial challenges.
• •Long-term outlook: steady mid-single-digit growth with steady technology-led product refresh cycles.